Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma

Robert M. Dean, Daniel H. Fowler, Wyndham H. Wilson, Jeanne Odom, Seth M. Steinberg, Catherine Chow, Claude Sportes, Ronald E. Gress, Michael R. Bishop

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Chemotherapy sensitivity has been identified as an important prognostic factor in reduced-intensity allogeneic stem cell transplantation (RIST) for non-Hodgkin lymphoma (NHL). However, the effect of uniform salvage chemotherapy before RIST has not been studied prospectively. We examined whether the response to prospectively administered uniform salvage therapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and fludarabine) influenced the subsequent outcome of RIST in 28 patients with relapsed or refractory NHL. After RIST, overall survival (OS) at 36 months is 49%, whereas event-free survival (EFS) is 32%. In Cox model analyses, the response to chemotherapy was the best predictor of OS (P = .0006) and EFS (P = .0006) after RIST. Differentiating stable disease from progressive disease after salvage chemotherapy strengthened the association with survival. Among chemotherapy-sensitive patients, the median OS and EFS have not been reached. In patients with stable disease, OS and EFS at 24 months are 50% and 25%, respectively. In contrast, only 1 patient with progressive disease during salvage therapy survived longer than 12 months. These prospective data confirm the favorable prognosis for chemotherapy-sensitive NHL after RIST and suggest that chemotherapy resistance is not an absolute contraindication to RIST for NHL patients with stable disease during salvage therapy.

Original languageEnglish (US)
Pages (from-to)593-599
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume11
Issue number8
DOIs
StatePublished - Aug 1 2005
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Drug Therapy
Salvage Therapy
Disease-Free Survival
Survival
Vincristine
Etoposide
Prednisone
Proportional Hazards Models
Doxorubicin
Cyclophosphamide

Keywords

  • Chemotherapy sensitivity
  • Non-Hodgkin lymphoma
  • Prognosis
  • Reduced-intensity allogeneic stem cell transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma. / Dean, Robert M.; Fowler, Daniel H.; Wilson, Wyndham H.; Odom, Jeanne; Steinberg, Seth M.; Chow, Catherine; Sportes, Claude; Gress, Ronald E.; Bishop, Michael R.

In: Biology of Blood and Marrow Transplantation, Vol. 11, No. 8, 01.08.2005, p. 593-599.

Research output: Contribution to journalArticle

Dean, RM, Fowler, DH, Wilson, WH, Odom, J, Steinberg, SM, Chow, C, Sportes, C, Gress, RE & Bishop, MR 2005, 'Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma', Biology of Blood and Marrow Transplantation, vol. 11, no. 8, pp. 593-599. https://doi.org/10.1016/j.bbmt.2005.04.005
Dean, Robert M. ; Fowler, Daniel H. ; Wilson, Wyndham H. ; Odom, Jeanne ; Steinberg, Seth M. ; Chow, Catherine ; Sportes, Claude ; Gress, Ronald E. ; Bishop, Michael R. / Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma. In: Biology of Blood and Marrow Transplantation. 2005 ; Vol. 11, No. 8. pp. 593-599.
@article{1e2b1eb856bb4da789872eff68e8dbf9,
title = "Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma",
abstract = "Chemotherapy sensitivity has been identified as an important prognostic factor in reduced-intensity allogeneic stem cell transplantation (RIST) for non-Hodgkin lymphoma (NHL). However, the effect of uniform salvage chemotherapy before RIST has not been studied prospectively. We examined whether the response to prospectively administered uniform salvage therapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and fludarabine) influenced the subsequent outcome of RIST in 28 patients with relapsed or refractory NHL. After RIST, overall survival (OS) at 36 months is 49{\%}, whereas event-free survival (EFS) is 32{\%}. In Cox model analyses, the response to chemotherapy was the best predictor of OS (P = .0006) and EFS (P = .0006) after RIST. Differentiating stable disease from progressive disease after salvage chemotherapy strengthened the association with survival. Among chemotherapy-sensitive patients, the median OS and EFS have not been reached. In patients with stable disease, OS and EFS at 24 months are 50{\%} and 25{\%}, respectively. In contrast, only 1 patient with progressive disease during salvage therapy survived longer than 12 months. These prospective data confirm the favorable prognosis for chemotherapy-sensitive NHL after RIST and suggest that chemotherapy resistance is not an absolute contraindication to RIST for NHL patients with stable disease during salvage therapy.",
keywords = "Chemotherapy sensitivity, Non-Hodgkin lymphoma, Prognosis, Reduced-intensity allogeneic stem cell transplantation",
author = "Dean, {Robert M.} and Fowler, {Daniel H.} and Wilson, {Wyndham H.} and Jeanne Odom and Steinberg, {Seth M.} and Catherine Chow and Claude Sportes and Gress, {Ronald E.} and Bishop, {Michael R.}",
year = "2005",
month = "8",
day = "1",
doi = "10.1016/j.bbmt.2005.04.005",
language = "English (US)",
volume = "11",
pages = "593--599",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma

AU - Dean, Robert M.

AU - Fowler, Daniel H.

AU - Wilson, Wyndham H.

AU - Odom, Jeanne

AU - Steinberg, Seth M.

AU - Chow, Catherine

AU - Sportes, Claude

AU - Gress, Ronald E.

AU - Bishop, Michael R.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Chemotherapy sensitivity has been identified as an important prognostic factor in reduced-intensity allogeneic stem cell transplantation (RIST) for non-Hodgkin lymphoma (NHL). However, the effect of uniform salvage chemotherapy before RIST has not been studied prospectively. We examined whether the response to prospectively administered uniform salvage therapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and fludarabine) influenced the subsequent outcome of RIST in 28 patients with relapsed or refractory NHL. After RIST, overall survival (OS) at 36 months is 49%, whereas event-free survival (EFS) is 32%. In Cox model analyses, the response to chemotherapy was the best predictor of OS (P = .0006) and EFS (P = .0006) after RIST. Differentiating stable disease from progressive disease after salvage chemotherapy strengthened the association with survival. Among chemotherapy-sensitive patients, the median OS and EFS have not been reached. In patients with stable disease, OS and EFS at 24 months are 50% and 25%, respectively. In contrast, only 1 patient with progressive disease during salvage therapy survived longer than 12 months. These prospective data confirm the favorable prognosis for chemotherapy-sensitive NHL after RIST and suggest that chemotherapy resistance is not an absolute contraindication to RIST for NHL patients with stable disease during salvage therapy.

AB - Chemotherapy sensitivity has been identified as an important prognostic factor in reduced-intensity allogeneic stem cell transplantation (RIST) for non-Hodgkin lymphoma (NHL). However, the effect of uniform salvage chemotherapy before RIST has not been studied prospectively. We examined whether the response to prospectively administered uniform salvage therapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and fludarabine) influenced the subsequent outcome of RIST in 28 patients with relapsed or refractory NHL. After RIST, overall survival (OS) at 36 months is 49%, whereas event-free survival (EFS) is 32%. In Cox model analyses, the response to chemotherapy was the best predictor of OS (P = .0006) and EFS (P = .0006) after RIST. Differentiating stable disease from progressive disease after salvage chemotherapy strengthened the association with survival. Among chemotherapy-sensitive patients, the median OS and EFS have not been reached. In patients with stable disease, OS and EFS at 24 months are 50% and 25%, respectively. In contrast, only 1 patient with progressive disease during salvage therapy survived longer than 12 months. These prospective data confirm the favorable prognosis for chemotherapy-sensitive NHL after RIST and suggest that chemotherapy resistance is not an absolute contraindication to RIST for NHL patients with stable disease during salvage therapy.

KW - Chemotherapy sensitivity

KW - Non-Hodgkin lymphoma

KW - Prognosis

KW - Reduced-intensity allogeneic stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=22344453861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22344453861&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2005.04.005

DO - 10.1016/j.bbmt.2005.04.005

M3 - Article

C2 - 16041309

AN - SCOPUS:22344453861

VL - 11

SP - 593

EP - 599

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -